Become a member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Nihonbashi Life Science HUB

Oct 25, 2018 9:00 AM - Oct 26, 2018 6:00 PM

8F, 1-5-5 Nihonbashi-muromachi, Chuo-ku, Tokyo, 103-0022 Japan

7th DIA Cardiac Safety Workshop in Japan

It will be a unique opportunity to learn of and discuss the current state and future directions of CV risk assessments and how to prepare for a new regulatory paradigm.

Back to Agenda

[Session 3] Abstract Session 1

Session Chair(s)

Naoki Furuyama, DVM, PhD

Medical Information & Communication, Japan Medical Affairs

Takeda Pharmaceutical Company Limited, Japan

Yuji Kumagai, MD, PhD

Professor, Kitasato Clinical Research Center

Kitasato University Hospital, Japan

Speaker(s)

Can we rely on automated ECG machine measurements for clinical trial decisions?

Robert Kleiman, MD

ERT, United States

Chief Medical Officer and Vice President, Global Cardiology

Heart Rate Correction When the Drug Affects Heart Rate

Georg Ferber

Statistik Georg Ferber GmbH, Switzerland

Statistical Consultant

Intensive QT investigation as standard practice in early clinical programs

Sanae Yasuda, PhD

Japan

Senior Director, Clinical Pharmacology, Medicine Development Center

Evaluation of a proposed novel biomarker, the JTpeak interval, for evaluation of proarrhythmic liability

Börje C. Darpö, MD, PhD

Clario, Sweden

Chief Scientific Officer, Cardiac Safety

Influence of Food on QT, J-Tpeak and Tpeak - Tend Intervals

Jorg Taubel, MD, FFPM

Richmond Pharmacology, United Kingdom

Chief Executive Officer

Have an account?